Redeye maintains its valuation of BioArctic at SEK 150 per share. BioArctic is the company in the amyloid-beta space with the most promising drug candidate (BAN2401), in our view. It has an interesting pipeline and solid financials. It has also a significant financial upside in the shape of milestone payments and royalties.